LEL Lilly(Eli)

 
TIDMLEL 
 
Date: June 19, 2012 
 
For Release: Immediately 
 
Refer to: (317) 276-5795 Mark Taylor 
 
 Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program 
 
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a 
dividend for the third quarter of 2012 of $0.49 a share on outstanding common 
stock. The dividend is payable September 10, 2012 to shareholders of record at 
the close of business on August 15, 2012. 
 
The Lilly board of directors has also authorized the resumption of a share 
repurchase program that was started in 2000, under which the company has thus 
far purchased $2.58 billion of shares of a total authorization of $3.0 billion. 
The company expects to complete this program by purchasing the remaining $420 
million in shares by the end of 2012. The company also anticipates resuming 
systematic share repurchases following the completion of the current program. 
The size and timing of these additional share repurchases will be subject to 
board approval and will be balanced with other cash flow considerations, 
including the funding of the company's dividend, capital expenditures, 
potential business development opportunities and worldwide macroeconomic 
conditions. 
 
"At Lilly, we're committed to providing a positive return to our shareholders 
through both a healthy dividend and stock price appreciation. Based on current 
market valuations and our confidence in Lilly's future, we believe that now is 
an excellent opportunity to resume buying back Lilly shares even as we maintain 
the dividend at least at its current level," said John Lechleiter, Ph.D., Lilly 
chairman, president, and chief executive officer. 
 
All purchases under the share repurchase program will be made on the open 
market at prevailing prices. Purchases will be made over a period to be 
determined by management of the company. Shares acquired will be retired. As of 
March 31, 2012 there were 1,116,982,662 shares of stock outstanding on a 
diluted basis. 
 
Lilly, a leading innovation-driven corporation, is developing a growing 
portfolio of pharmaceutical products by applying the latest research from its 
own worldwide laboratories and from collaborations with eminent scientific 
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - 
through medicines and information - for some of the world's most urgent medical 
needs. Additional information about Lilly is available at www.lilly.com. F-LLY 
 
This press release contains forward-looking statements that are based on 
management's current expectations, but actual results may differ materially due 
to various factors. There is no guarantee the company will be able to complete 
its planned 2012 share repurchases or will continue repurchasing shares in 2013 
or beyond. There are significant risks and uncertainties in pharmaceutical 
research and development. There can be no guarantees with respect to pipeline 
products that the products will receive the necessary clinical and 
manufacturing regulatory approvals or that they will prove to be commercially 
successful. Pharmaceutical products can develop unexpected safety or efficacy 
concerns. The company's results may also be affected by such factors as 
competitive developments affecting current products; market uptake of recently 
launched products; the timing of anticipated regulatory approvals and launches 
of new products; regulatory actions regarding currently marketed products; 
issues with product supply; regulatory changes or other developments; 
regulatory compliance problems or government investigations; patent disputes; 
changes in patent law or regulations related to data-package exclusivity; other 
litigation involving current or future products; the impact of governmental 
actions regarding pricing, importation, and reimbursement for pharmaceuticals, 
including U.S. health care reform; changes in tax law; asset impairments and 
restructuring charges; acquisitions and business development transactions; and 
the impact of exchange rates and global macroeconomic conditions. For 
additional information about the factors that affect the company's business, 
please see the company's latest Form 10-Q and Form 10-K filed with the U.S. 
Securities and Exchange Commission. The company undertakes no duty to update 
forward-looking statements. 
 
                                     # # # 
 
 
 
Eli Lilly and Company 
Lilly Corporate Center 
Indianapolis, Indiana 46285 
U.S.A. 
www.lilly.com 
 
 
 
 
 
 
END 
 

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025